Article Versions Notes

Walls AB, Bengaard AK, Iversen E, Nguyen CN, Kallemose T, Juul-Larsen HG, Jawad BN, Hornum M, Andersen O, Eugen-Olsen J, et al. Utility of suPAR and NGAL for AKI Risk Stratification and Early Optimization of Renal Risk Medications among Older Patients in the Emergency Department. Pharmaceuticals. 2021; 14(9):843. https://doi.org/10.3390/ph14090843

Walls, Anne Byriel, Anne Kathrine Bengaard, Esben Iversen, Camilla Ngoc Nguyen, Thomas Kallemose, Helle Gybel Juul-Larsen, Baker Nawfal Jawad, Mads Hornum, Ove Andersen, Jesper Eugen-Olsen, and et al. 2021. "Utility of suPAR and NGAL for AKI Risk Stratification and Early Optimization of Renal Risk Medications among Older Patients in the Emergency Department" Pharmaceuticals 14, no. 9: 843. https://doi.org/10.3390/ph14090843

Walls, A. B., Bengaard, A. K., Iversen, E., Nguyen, C. N., Kallemose, T., Juul-Larsen, H. G., Jawad, B. N., Hornum, M., Andersen, O., Eugen-Olsen, J., & Houlind, M. B. (2021). Utility of suPAR and NGAL for AKI Risk Stratification and Early Optimization of Renal Risk Medications among Older Patients in the Emergency Department. Pharmaceuticals, 14(9), 843. https://doi.org/10.3390/ph14090843